

DATA SHEET

For research use only. Not for use in humans.

Reagent:	Monoclonal Anti-Human Immunodeficiency Virus Type 1 (HIV-1) gp120 Protein (VRC01, produced <i>in vitro</i>)
Catalog Number:	ARP-12033
Lot Number:	200207
Provided:	Each vial of ARP-12033 contains approximately 500 µg of purified antibody at a concentration of 1.04 mg/mL in PBS, pH 7.2. Endotoxin content is 0.1 EU/mg. Purity is approximately 95% by densitometric analysis of the Coomassie Blue-stained SDS-PAGE gel under non-reducing conditions.
Description:	ARP-12033 is a recombinant monoclonal antibody to HIV-1 gp120, specifically the CD4-binding site.
Host:	Human
Special Characteristics:	This recombinant antibody was produced in a 293-6E expression system and purified by protein A affinity resin chromatography. This antibody originates from the B-cells of a HIV-1 infected donor. VRC01 neutralizes a broad variety of laboratory HIV-1 strains and primary isolates and is active against all major subtypes. Suggested working dilutions are 5 µg/mL for ELISA and 10 µg/mL for HIV-1 neutralization.
Titer:	The user should determine the optimal concentration for any application.
Recommended Storage:	Keep at 4°C only for short-term storage and -80°C for long-term storage. Avoid freeze-thaw cycles as reagent degradation may result.
Contributor:	Xueling Wu, Zhi-Yong Yang, Yuxing Li, Gary Nabel and John Mascola
Isotype:	IgG1, kappa
References:	Wu, X., et al. "Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1." <i>Science</i> 329 (2010): 856-861. PubMed: 20616233.
Citation:	Acknowledgment for publications should read "The following reagent was obtained through BEI Resources, NIAID, NIH: Monoclonal Anti-Human Immunodeficiency Virus Type 1 (HIV-1) gp120 Protein (VRC01, produced <i>in vitro</i>), ARP-12033."
Biosafety Level: 1	Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. <i>Biosafety in Microbiological and Biomedical Laboratories (BMBL)</i> . Current Edition. Washington, DC: U.S. Government Printing Office.
Disclaimers:	You are authorized to use this product for research use only. It is not intended for human use. Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at www.beiresources.org .

While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government makes any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate.

This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products.

Use Restrictions:

This material is distributed for internal research purposes only. This material, its product or its derivatives may not be distributed to third parties. Except as performed under a U.S. Government contract, individuals contemplating commercial use of the material, its products or its derivatives must contact the contributor to determine if a license is required. U.S. Government contractors may need a license before first commercial sale.

Note:

Scientists at for-profit institutions or who intend commercial use of this reagent must contact NIAID Technology Transfer and Intellectual Property Office at the following email address: NIAIDAIDSReagent@niaid.nih.gov, before the reagent can be released.

ATCC® is a trademark of the American Type Culture Collection.

